论文部分内容阅读
目的观察伊立替康联合洛铂治疗复发的广泛期小细胞肺癌(SCLC)的疗效及毒副反应。方法选取2007年8月至2010年8月在福建省肿瘤医院住院的复发广泛期小细胞肺癌患者40例,予以洛铂35mg/m2第1天,伊立替康100mg/m2第1、8天,每21d为一周期,每个周期结束复查CT评价疗效,观察其疗效及毒副反应。结果完全缓解(CR)0例,部分缓解(PR)14例,疾病稳定(SD)12例,疾病进展(PD)14例,客观缓解率(ORR)35%,疾病控制率(DCR)65%,中位无进展生存期(PFS)4.2个月,中位生存期(OS)7.9个月,主要毒副反应为血液学毒性、恶心、呕吐及腹泻,全组无毒性相关死亡。结论伊立替康联合洛铂可用于治疗复发广泛期小细胞肺癌,不良反应可以耐受。
Objective To observe the efficacy and side effects of irinotecan combined with lobaplatin in the treatment of recurrent widespread small cell lung cancer (SCLC). Methods Forty patients with recurrent extensive small cell lung cancer who were hospitalized in Fujian Provincial Tumor Hospital from August 2007 to August 2010 were enrolled. The patients were treated with 35 mg / Every 21d for a cycle, the end of each cycle to review CT evaluation of efficacy, to observe the efficacy and side effects. Results There were 0 cases of complete remission (CR), 14 cases of partial remission (PR), 12 cases of stable disease (SD), 14 cases of progressive disease (PD), objective response rate of 35%, disease control rate (DCR) . The median progression-free survival (PFS) was 4.2 months. The median survival time (OS) was 7.9 months. The main toxicities were hematological toxicity, nausea, vomiting and diarrhea. All the patients were non-toxic. Conclusion Irinotecan combined with lobaplatin can be used in the treatment of recurrent small-cell lung cancer. The adverse reactions can be tolerated.